CT Scans Can Catch Sarcoidosis Severity That Breathing Tests Miss
CT scans can catch sarcoidosis severity that breathing tests miss. That's the finding from a National Jewish Health study published in April 2026, and it matters because current clinical guidelines don't call for CT scans in routine sarcoidosis evaluation.
The study analyzed CT scans from over 900 patients. Nearly two-thirds of patients with fibrosis on their scans had abnormal breathing tests, compared with about one-third of those without visible fibrosis (National Jewish Health, Lung Scans Can Reveal Important Differences in Sarcoidosis Severity, April 2026; n=900+ patients; https://www.nationaljewish.org/about-us/news/press-releases/2026-news/lung-scans-can-reveal-important-differences-in-sarcoidosis-severity-according-to-new-study).
That's a problem. If the scan shows fibrosis but the breathing test doesn't flag it yet, you're catching severity earlier – before lung function drops enough to measure. The gap between imaging and function testing means some patients showing fibrotic changes on CT would be missed by the current standard of care.
I live with pulmonary fibrosis, and sarcoidosis is the most likely cause of it. I have nodules and fibroids in my kidneys and liver as well, and my lung lymph nodes are "crystalized." The fibrotic process is the endpoint that matters. Scarring doesn't reverse. Catching it earlier means more time to try interventions before the lung tissue is too far gone.
Sarcoidosis is inflammatory lung disease that can progress to fibrosis. The immune system forms granulomas (clusters of inflammatory cells) in the lungs, and in some patients those granulomas lead to permanent scarring. The imaging study shows that CT patterns can signal who's heading that direction, even when their breathing tests still look acceptable.
There's preclinical work happening too. A study published in August 2026 found that blocking CXCR6 (a chemokine receptor) reduced granuloma formation and collagen deposition in mouse models of pulmonary fibrosis (International Immunopharmacology, August 2026; https://www.sciencedirect.com/science/article/pii/S1567576926006910). Collagen deposition is fibrosis – blocking it means less scarring. The study is early-stage (mouse models, not human trials yet), but CXCR6 is now a named therapeutic target.
And Merck started a trial in November. Tulisokibart is being tested in a phase 3 study to see if it delays worsening compared with placebo (ClinicalTrials.gov, NCT07867938, started 2026-11-03, last updated 2026-11-09; https://clinicaltrials.gov/study/NCT07867938).
None of this changes the fact that I have a terminal diagnosis. But the imaging finding is actionable. If CT can catch severity earlier than pulmonary function tests, that's a tool clinicians should be using. The study authors noted that guidelines don't indicate the need for CT in sarcoidosis evaluation. That should change.
For patients with inflammatory lung disease, earlier detection of fibrotic changes means more time to adjust treatment before scarring becomes the dominant process. Fibrosis is the one-way door. You want to know you're approaching it before you're through it.
The CXCR6 work is promising because it targets the mechanism – not managing symptoms, but blocking the pathway that lays down scar tissue. That's the kind of research that could eventually matter for pulmonary fibrosis more broadly, not just sarcoidosis. Different triggers, same endpoint.
I watch this research because sarcoidosis is the most likely cause of the disease I'm living with. Sarcoidosis can lead to pulmonary fibrosis. I have pulmonary fibrosis. Anything that catches fibrosis earlier or slows its progression is worth following.
The CT finding is the immediately useful piece. Imaging can show what function tests miss. That knowledge exists now, and the guidelines should reflect it.
